Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy.
about
Host Responses in the Link Between Periodontitis and Rheumatoid ArthritisSpotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to dateIdentification of IL6R and chromosome 11q13.5 as risk loci for asthmaIdentification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy.Review of Systemic Immunosuppression for Autoimmune UveitisEffect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study.Endothelial progenitor cells in cardiovascular disease and chronic inflammation: from biomarker to therapeutic agent.IL-6 trans-signaling increases expression of airways disease genes in airway smooth muscleInhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+ breast cancers.A novel approach to genome-wide association analysis identifies genetic associations with primary biliary cholangitis and primary sclerosing cholangitis in Polish patients.Serum Levels of IL-6 and TNF-α May Correlate with Activity and Severity of Rheumatoid Arthritis.Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis.Dosing of Intravenous Tocilizumab in a Real-World Setting of Rheumatoid Arthritis: Analyses from the Corrona Registry.Non-tumor necrosis factor-based biologic therapies for rheumatoid arthritis: present, future, and insights into pathogenesis.Road to remission: a comprehensive review of therapy in uveitis.Interleukin-23 as a potential therapeutic target for rheumatoid arthritis.Cellular and molecular mechanisms of autoimmune disease.IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential.Interleukin-6 and cytochrome-P450, reason for concern?Mast cells: a new target in the treatment of complex regional pain syndrome?Rituximab and tocilizumab for the treatment of rheumatoid arthritis.Chemopreventive effects of a curcumin-like diarylpentanoid [2,6-bis(2,5-dimethoxybenzylidene)cyclohexanone] in cellular targets of rheumatoid arthritis in vitro.Severe sepsis caused by Aeromonas hydrophila in a patient using tocilizumab: a case report.Severe Pulmonary Suppuration with Infection-Induced Systemic Inflammatory Response Syndrome following Tongue Cancer Surgery in a Patient Undergoing Tocilizumab Therapy for Rheumatoid Arthritis.Th17 response and inflammatory autoimmune diseases.Does tocilizumab contribute to elevation of rheumatoid factor and induction of paradoxical syaloadenitis in rheumatoid arthritis patients?Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis.Nodular progression of lentigo malignant melanoma during a treatment with tocilizumab: cause or coincidence?Periodontal, salivary and IL-6 status in rheumatoid arthritis patients. A cross-sectional study.Tofacitinib Therapy for Rheumatoid Arthritis: A Direct Comparison Study between Biologic-naïve and Experienced Patients.Ocular surface findings in patients with rheumatoid arthritis under methotrexate or biological agent therapy.Norisoboldine inhibits the production of interleukin-6 in fibroblast-like synoviocytes from adjuvant arthritis rats through PKC/MAPK/NF-κB-p65/CREB pathways.
P2860
Q27016197-EB683EFF-C87A-4219-B44B-A83FC0104F59Q28076558-7257A11F-E986-4194-A6FA-E091B6A42778Q29417065-2E4E7C57-1BAC-4950-BBD9-B0D14C27D697Q33921579-CB6F804B-9146-4F53-928A-04278EA97DA3Q34627012-598EB303-665A-442E-B397-6C38F5437443Q35352554-8E61919B-D559-43A8-90AB-057A80919BA0Q35774189-EE4FB33D-9A06-4AED-AD3F-790D47E8EE00Q35859326-252E23CE-9D1D-46DF-98D0-491174582301Q35952745-AF628F2E-469A-4046-81DB-A1E8352FA4F3Q36241388-102DA03E-E9B3-4C03-99D7-7FA2D3E9EE70Q36412824-FFB618B2-A1D8-4529-9DCD-DA37BE458B1CQ36679769-7C247E0F-8CD7-4345-98D1-47BD4875C3FBQ37208456-8A247880-3310-468A-8381-C4619499C2CAQ37388213-CF7995C3-7447-4155-8EAC-73E2F5265A29Q37936459-CA30E5C9-20B8-4152-AB60-6B5C16546017Q37947514-C8C0403E-38FE-4D14-A04C-08AB670FE4BDQ37959331-9E831A05-7064-4ED2-AE48-FE523B0F785CQ37983096-3D773A2B-1765-4E36-A890-9A1BEA54946BQ37997359-E95F228E-9A31-4479-9825-3A6D40A78A16Q38089303-B6AE2E27-8493-45CB-850B-7FAC9443FB47Q38234629-3F8F1159-54F3-46CF-BC21-9CC4C20E4203Q38994619-00816711-9DED-48D6-BDAB-68C188685E07Q39043565-AF12AF00-1EAC-418B-B007-7A36139C63AEQ39599075-D68C1C7A-F943-40B0-81F6-5AEE986B26F6Q40110959-A9DC17B0-95A9-44CB-9D3B-653FEFCAD2C5Q42254666-9D82BDF6-CC3A-439E-B805-3893B54140BBQ42578542-8EA16EDD-756D-4116-B1CA-F086918AD1FCQ45101917-C434B941-F2BE-41F9-902D-22C7D43E50F8Q47153616-D0859C9C-7222-4DBC-894E-617683748349Q49901596-137E414B-2EEB-40EC-937C-FD350280034EQ53176613-08D49970-F631-44F2-969E-AF9388709797Q54519453-F1CE1071-7938-4745-A700-BF91DD6AF23B
P2860
Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Interleukin-6 inhibition for t ...... review of tocilizumab therapy.
@ast
Interleukin-6 inhibition for t ...... review of tocilizumab therapy.
@en
Interleukin-6 inhibition for t ...... review of tocilizumab therapy.
@nl
type
label
Interleukin-6 inhibition for t ...... review of tocilizumab therapy.
@ast
Interleukin-6 inhibition for t ...... review of tocilizumab therapy.
@en
Interleukin-6 inhibition for t ...... review of tocilizumab therapy.
@nl
prefLabel
Interleukin-6 inhibition for t ...... review of tocilizumab therapy.
@ast
Interleukin-6 inhibition for t ...... review of tocilizumab therapy.
@en
Interleukin-6 inhibition for t ...... review of tocilizumab therapy.
@nl
P2860
P921
P356
P1476
Interleukin-6 inhibition for t ...... review of tocilizumab therapy.
@en
P2093
Aarat M Patel
Larry W Moreland
P2860
P304
P356
10.2147/DDDT.S14099
P407
P577
2010-10-01T00:00:00Z